[go: up one dir, main page]

SK287252B6 - Farmaceutický prípravok s obsahom benzamidového derivátu - Google Patents

Farmaceutický prípravok s obsahom benzamidového derivátu Download PDF

Info

Publication number
SK287252B6
SK287252B6 SK261-2002A SK2612002A SK287252B6 SK 287252 B6 SK287252 B6 SK 287252B6 SK 2612002 A SK2612002 A SK 2612002A SK 287252 B6 SK287252 B6 SK 287252B6
Authority
SK
Slovakia
Prior art keywords
acid
pharmaceutical preparation
acidic
preparation according
hydrochloride
Prior art date
Application number
SK261-2002A
Other languages
English (en)
Slovak (sk)
Other versions
SK2612002A3 (en
Inventor
Masahiko Ishibashi
Masahiro Sakabe
Ikuo Sakai
Tsuneji Suzuki
Tomoyuki Ando
Original Assignee
Schering Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Aktiengesellschaft filed Critical Schering Aktiengesellschaft
Publication of SK2612002A3 publication Critical patent/SK2612002A3/sk
Publication of SK287252B6 publication Critical patent/SK287252B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
SK261-2002A 1999-08-30 2000-08-29 Farmaceutický prípravok s obsahom benzamidového derivátu SK287252B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP24244499A JP2001081031A (ja) 1999-08-30 1999-08-30 溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤
PCT/EP2000/008421 WO2001016106A1 (en) 1999-08-30 2000-08-29 Benzamide formulation with histone deacetylase inhibitor activity

Publications (2)

Publication Number Publication Date
SK2612002A3 SK2612002A3 (en) 2002-09-10
SK287252B6 true SK287252B6 (sk) 2010-04-07

Family

ID=17089193

Family Applications (1)

Application Number Title Priority Date Filing Date
SK261-2002A SK287252B6 (sk) 1999-08-30 2000-08-29 Farmaceutický prípravok s obsahom benzamidového derivátu

Country Status (32)

Country Link
US (1) US6638530B1 (pt)
EP (1) EP1208086B1 (pt)
JP (2) JP2001081031A (pt)
KR (1) KR100712640B1 (pt)
CN (1) CN1147472C (pt)
AR (1) AR025434A1 (pt)
AT (1) ATE318258T1 (pt)
AU (1) AU773617B2 (pt)
BG (1) BG65544B1 (pt)
BR (1) BR0013648A (pt)
CA (1) CA2382886C (pt)
CZ (1) CZ301737B6 (pt)
DE (1) DE60026144T2 (pt)
DK (1) DK1208086T3 (pt)
EE (1) EE05063B1 (pt)
ES (1) ES2259289T3 (pt)
HK (1) HK1046277B (pt)
HR (1) HRP20020182B1 (pt)
HU (1) HUP0203330A3 (pt)
IL (2) IL148357A0 (pt)
MX (1) MXPA02002090A (pt)
NO (1) NO322532B1 (pt)
NZ (1) NZ517520A (pt)
PL (1) PL201274B1 (pt)
PT (1) PT1208086E (pt)
RU (1) RU2260428C2 (pt)
SI (1) SI1208086T1 (pt)
SK (1) SK287252B6 (pt)
TW (1) TWI268778B (pt)
UA (1) UA72541C2 (pt)
WO (1) WO2001016106A1 (pt)
ZA (1) ZA200201424B (pt)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658938B2 (en) * 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US20070148228A1 (en) * 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
US8119159B2 (en) * 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
WO2002078669A1 (fr) * 2001-03-30 2002-10-10 Takeda Chemical Industries, Ltd. Solutions medicinales
AU2006252047B2 (en) * 2001-09-14 2010-02-11 Methylgene Inc. Inhibitors of histone deacetylase
US7868204B2 (en) 2001-09-14 2011-01-11 Methylgene Inc. Inhibitors of histone deacetylase
MXPA04002397A (es) 2001-09-14 2004-12-02 Methylgene Inc Inhibidores de histona deacetilasa.
US6897220B2 (en) 2001-09-14 2005-05-24 Methylgene, Inc. Inhibitors of histone deacetylase
US6706686B2 (en) 2001-09-27 2004-03-16 The Regents Of The University Of Colorado Inhibition of histone deacetylase as a treatment for cardiac hypertrophy
WO2003032921A2 (en) 2001-10-16 2003-04-24 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases and cancer of the brain
JPWO2003070691A1 (ja) * 2002-02-21 2005-06-09 財団法人大阪産業振興機構 Ｎ−ヒドロキシカルボキサミド誘導体
US7456219B2 (en) 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
US7148257B2 (en) 2002-03-04 2006-12-12 Merck Hdac Research, Llc Methods of treating mesothelioma with suberoylanilide hydroxamic acid
MXPA04008577A (es) 2002-03-04 2005-07-13 Aton Pharma Inc Metodos para inducir diferenciacion terminal.
EP1490013B1 (en) 2002-03-07 2010-02-17 University Of Delaware Methods for enhancing oligonucleotide-mediated nucleic acid sequence alteration using compositions comprising hydroxyurea
GB0209715D0 (en) * 2002-04-27 2002-06-05 Astrazeneca Ab Chemical compounds
DE10233412A1 (de) * 2002-07-23 2004-02-12 4Sc Ag Neue Verbindungen als Histondeacetylase-Inhibitoren
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7250514B1 (en) 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
GB0226855D0 (en) * 2002-11-18 2002-12-24 Queen Mary & Westfield College Histone deacetylase inhibitors
US7244751B2 (en) * 2003-02-14 2007-07-17 Shenzhen Chipscreen Biosciences Ltd. Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity
US7169801B2 (en) 2003-03-17 2007-01-30 Takeda San Diego, Inc. Histone deacetylase inhibitors
CN100455564C (zh) * 2003-09-12 2009-01-28 深圳微芯生物科技有限责任公司 组蛋白去乙酰化酶抑制剂及其药用制剂的制备和应用
WO2005030705A1 (en) * 2003-09-24 2005-04-07 Methylgene, Inc. Inhibitors of histone deacetylase
CN101445469B (zh) * 2003-09-24 2013-02-13 梅特希尔基因公司 组蛋白脱乙酰基酶抑制剂
EP1696898B1 (en) * 2003-12-02 2015-11-18 The Ohio State University Research Foundation Zn 2+ -chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors
US20080057529A1 (en) * 2003-12-18 2008-03-06 Michele Pallaoro Method for Identifying Histone Deacetylase Inhibitors
US7253204B2 (en) 2004-03-26 2007-08-07 Methylgene Inc. Inhibitors of histone deacetylase
WO2006066133A2 (en) 2004-12-16 2006-06-22 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20100087328A1 (en) * 2005-03-01 2010-04-08 The Regents Of The University Of Michigan Brm expression and related diagnostics
US7604939B2 (en) * 2005-03-01 2009-10-20 The Regents Of The University Of Michigan Methods of identifying active BRM expression-promoting HDAC inhibitors
EP1896436A2 (en) 2005-05-11 2008-03-12 Takeda San Diego, Inc. Histone deacetylase inhibitors
TWI365068B (en) 2005-05-20 2012-06-01 Merck Sharp & Dohme Formulations of suberoylanilide hydroxamic acid and methods for producing same
JP2009501236A (ja) 2005-07-14 2009-01-15 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
US20100152188A1 (en) * 2005-08-05 2010-06-17 Akella Satya Surya Visweswara Srinivas Novel Heterocyclic Compounds
KR101191322B1 (ko) * 2006-04-07 2012-10-16 메리온 리서치 Ⅲ 리미티드 증진제를 함유하는 고형 경구용 투여 제형
CN101466670B (zh) 2006-04-07 2013-04-17 梅特希尔基因公司 组蛋白脱乙酰酶抑制剂
US20070292512A1 (en) * 2006-06-09 2007-12-20 Merrion Research Ii Limited Solid Oral Dosage Form Containing an Enhancer
CA2680838A1 (en) 2007-03-28 2008-10-16 Santen Pharmaceutical Co., Ltd. Intraocular pressure-lowering agent comprising compound having histone deacetylase inhibitory effect as active ingredient
WO2009067808A1 (en) * 2007-11-27 2009-06-04 Ottawa Health Research Institute Amplification of cancer-specific oncolytic viral infection by histone deacetylase inhibitors
WO2009126662A1 (en) * 2008-04-08 2009-10-15 Syndax Pharmaceuticals, Inc. Administration of an inhibitor of hdac, an inhibitor of her-2, and a selective estrogen receptor modulator
CA2723558A1 (en) * 2008-05-07 2009-11-12 Merrion Research Iii Limited Compositions of gnrh related compounds and processes of preparation
EP2285376A4 (en) * 2008-05-16 2011-07-20 Chipscreen Biosciences Ltd 6-AMINONICOTINAMIDE DERIVATIVES FORMING POWERFUL AND SELECTIVE HISTONE DEACETYLASE INHIBITORS
WO2010011700A2 (en) 2008-07-23 2010-01-28 The Brigham And Women's Hospital, Inc. Treatment of cancers characterized by chromosomal rearrangement of the nut gene
CA2751854A1 (en) * 2009-02-25 2010-09-02 Merrion Research Iii Limited Composition and drug delivery of bisphosphonates
US9089484B2 (en) 2010-03-26 2015-07-28 Merrion Research Iii Limited Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
US8802114B2 (en) 2011-01-07 2014-08-12 Merrion Research Iii Limited Pharmaceutical compositions of iron for oral administration
CN103172540B (zh) * 2013-03-18 2015-07-01 潍坊博创国际生物医药研究院 苯甘氨酸类组蛋白去乙酰酶抑制剂及其制备方法和应用
WO2015051035A1 (en) 2013-10-01 2015-04-09 The J. David Gladstone Institutes Compositions, systems and methods for gene expression noise drug screening and uses thereof
WO2016120378A1 (en) 2015-01-29 2016-08-04 Novo Nordisk A/S Tablets comprising glp-1 agonist and enteric coating
DK3317281T3 (da) 2015-07-02 2020-06-15 Acerta Pharma Bv Faste former og formuleringer af (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamid
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
CN109715141A (zh) * 2016-07-08 2019-05-03 兰迪斯制药公司 治疗和/或预防溶酶体贮积病和其它单基因代谢性疾病的组合物和方法
WO2018222572A1 (en) * 2017-06-01 2018-12-06 Warner Babcock Institute For Green Chemistry, Llc Non-covalent derivatives and methods of treatment
US20180353446A1 (en) * 2017-06-07 2018-12-13 Ranedis Pharmaceuticals, Llc Compositions and methods of treating and/or preventing cancer
ES2977747T3 (es) 2019-04-25 2024-08-29 Fuji Pharma Co Ltd Preparado farmacéutico y procedimiento para producirlo
CN112294810B (zh) * 2019-07-29 2024-03-01 深圳微芯生物科技股份有限公司 含有西达本胺和表面活性剂的药物组合物
CA3199945A1 (en) 2020-10-28 2022-05-05 Kinopharma, Inc. Pharmaceutical composition for preventing or treating viral perivaginal disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI0956865T2 (sl) * 1996-08-12 2011-04-29 Mitsubishi Pharma Corp Zdravila, ki obsegajo inhibitor Rho-kinaze
US6174905B1 (en) * 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
JP3354090B2 (ja) * 1996-09-30 2002-12-09 シエーリング アクチエンゲゼルシャフト 分化誘導剤
JP4405602B2 (ja) * 1998-04-16 2010-01-27 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト ヒストン脱アセチル化酵素阻害剤
JP2000256194A (ja) * 1999-01-06 2000-09-19 Mitsui Chemicals Inc 核内レセプタ作動薬およびその効果増強剤
JP2001064177A (ja) * 1999-08-16 2001-03-13 Schering Ag ベンズアミド誘導体を有効成分とする製剤

Also Published As

Publication number Publication date
MXPA02002090A (es) 2003-08-20
CZ301737B6 (cs) 2010-06-09
KR100712640B1 (ko) 2007-05-02
DK1208086T3 (da) 2006-06-19
HK1046277A1 (en) 2003-01-03
HK1046277B (zh) 2004-11-26
BR0013648A (pt) 2002-05-07
DE60026144D1 (de) 2006-04-27
NO20020952D0 (no) 2002-02-27
AR025434A1 (es) 2002-11-27
NO20020952L (no) 2002-03-20
TWI268778B (en) 2006-12-21
NZ517520A (en) 2003-05-30
PT1208086E (pt) 2006-07-31
JP2003508386A (ja) 2003-03-04
CA2382886C (en) 2009-06-09
CN1371366A (zh) 2002-09-25
PL353063A1 (en) 2003-10-06
SK2612002A3 (en) 2002-09-10
SI1208086T1 (sl) 2006-08-31
HUP0203330A2 (hu) 2003-02-28
AU773617B2 (en) 2004-05-27
CZ2002724A3 (cs) 2002-07-17
EE05063B1 (et) 2008-08-15
EP1208086B1 (en) 2006-02-22
EE200200097A (et) 2003-04-15
NO322532B1 (no) 2006-10-23
AU6841600A (en) 2001-03-26
CA2382886A1 (en) 2001-03-08
JP2001081031A (ja) 2001-03-27
PL201274B1 (pl) 2009-03-31
HUP0203330A3 (en) 2004-03-01
ZA200201424B (en) 2002-11-27
ES2259289T3 (es) 2006-10-01
IL148357A0 (en) 2002-09-12
RU2260428C2 (ru) 2005-09-20
HRP20020182A2 (en) 2004-02-29
EP1208086A1 (en) 2002-05-29
CN1147472C (zh) 2004-04-28
DE60026144T2 (de) 2006-11-16
WO2001016106A1 (en) 2001-03-08
US6638530B1 (en) 2003-10-28
BG65544B1 (bg) 2008-11-28
ATE318258T1 (de) 2006-03-15
UA72541C2 (en) 2005-03-15
IL148357A (en) 2006-12-10
BG106439A (en) 2002-11-29
KR20020023424A (ko) 2002-03-28
HRP20020182B1 (en) 2007-08-31

Similar Documents

Publication Publication Date Title
SK287252B6 (sk) Farmaceutický prípravok s obsahom benzamidového derivátu
EP1683524B1 (en) Solid dispersion or medicinal solid dispersion preparation of phenylalanine derivative
ES2596291T3 (es) Formulaciones farmacéuticas que comprenden derivados de 1-(beta-d-glucopiranosil)-2-tienilmetilbenceno como inhibidores de sglt
US20090191265A1 (en) Capsule Formulation of Pirfenidone and Pharmaceutically Acceptable Excipients
US20230190732A1 (en) Pharmaceutical composition containing nitroxoline prodrug, and preparation method and application therefor
RU2257206C2 (ru) Фармацевтическое средство, содержащее производное бензамида в качестве активного ингредиента
KR102301743B1 (ko) 에피나코나졸 경구용 조성물
WO1989006959A1 (en) Pharmaceutical composition having improved releasability
KR20190064208A (ko) 피마살탄을 포함하는 고체 분산체
KR20190064210A (ko) 피마살탄을 포함하는 약학적 조성물
KR910004481B1 (ko) 용출성이 개량된 제제 조성물
AU2013201986A1 (en) Capsule Formulation Of Pirfenidone And Pharmaceutically Acceptable Excipients

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20110829